What: The CDC formally warned doctors Tuesday about counterfeit Botox that has sickened 22 people across 11 states. Negative symptoms were first reported in November, and most recently in March.
Why it matters: Now bad Botox reactions will officially be on physicians’ radar screens, especially if patients present with “localized paralysis.”
Source: Reuters
Trump promotes IVF access while cutting the team responsible for tracking it.
Federal research grants for women’s health are drying up under new Musk budget.
The influential Women’s Health Initiative will shut down without federal support.
Hormone therapy may lower a genetic heart risk factor, new WHI data suggests.
JAMA editorial calls for uniform lactation training among healthcare workers.
Maternal deaths due to cardiovascular issues more than doubled in the US between 1999 and 2022, with Black women and people in Southern states facing increased risk.
Legislators push for regulation and oversight of anti-abortion pregnancy centers.
One-third of patients spend more than $50,000 on fertility treatments, according to a new survey.
Once academic, now viral—this disinfectant may be the most powerful skin-safe cleanser yet.
The Trump administration ends the Pregnancy Risk Assessment Monitoring System (PRAMS), a long-standing CDC data tool.
Luxury spa resort launches new “Inner Glow” retreat focused on hormone health and long-term wellness.
Women who start menopause before age 40 may face faster cognitive decline.
Cosmo breaks down Botox alternatives—and why your injector matters most.
Study finds no mass OBGYN flight from states with abortion bans—yet.
New GLP-1 pill for diabetes patients shows 7%+ weight loss, boosting Eli Lilly stock.
Trump administration floats baby bonuses, fertility funding, and fertility-focused Fulbrights.
The influential Women’s Health Initiative will shut down without federal support.
NWLC report warns that birth control access is increasingly under threat post-Roe.
Study identifies fast, simple method for predicting life-threatening postpartum bleeding.
Promising cancer immunotherapy study delayed due to NIH layoffs.